Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine and Trastuzumab in HER2+ Metastatic Breast Cancer
NCT00193063Phase 2Completed
- Sponsor
- SCRI Development Innovations
- Start
- Jul 2001
- Primary completion
- May 2009
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Engineered Antibody Formats
01
Overview
A Phase 2 trial of gemcitabine, trastuzumab in breast cancer, sponsored by SCRI Development Innovations. Started Jul 2001; status: completed.
02
Drugs
gemcitabinetrastuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00193063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00193063.